An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer

BACKGROUND: KRAS mutations are the most frequent oncogenic aberration in lung adenocarcinoma. KRAS mutant isoforms differentially shape tumour biology and influence drug responses. This heterogeneity challenges the development of effective therapies for patients with KRAS-driven non-small cell lung...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Wang, Haiyun, Lv, Qi, Xu, Yue, Cai, Zhaoqing, Zheng, Jie, Cheng, Xiaojie, Dai, Yao, Jänne, Pasi A., Ambrogio, Chiara, Köhler, Jens
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945285/
https://ncbi.nlm.nih.gov/pubmed/31668570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.10.012
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados